Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Low molecular weight heparin buccal spray - Generex Biotechnology Corporation

Drug Profile

Low molecular weight heparin buccal spray - Generex Biotechnology Corporation

Alternative Names: LMW heparin buccal spray; Low molecular weight heparin oral spray

Latest Information Update: 15 Jan 2013

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Generex Biotechnology Corporation
  • Class Low molecular weight heparins
  • Mechanism of Action Antithrombin III stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Deep vein thrombosis

Most Recent Events

  • 01 Jan 2013 Low molecular weight heparin buccal spray is available for licensing as of 01 Jan 2013. \(http://www.generex.com/\)
  • 31 May 2004 No development reported - Phase-I for Deep vein thrombosis in Canada (Buccal)
  • 14 May 2002 Phase-I clinical trials in Deep vein thrombosis in Canada (Buccal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top